Call 24/7:

1-800-818-4511

Ibogaine Treatment Before and After Lab One

pexels luke barky 2899726

The patient underwent an 8-day ibogaine treatment regimen. The patient received ibogaine treatment on 16/03/2021 (568 mg) and a booster dose on 22/03/2021 (100 mg). An additional booster dose was administered on 19/03/2021 (100 mg) and 23/03/2021 (100 mg). The treatment regimen appears to have contributed to the observed improvements in the patient’s health parameters.

This comprehensive blood report highlights a patient’s health parameters before and after ibogaine treatment. Each parameter is discussed separately, emphasising any significant changes observed post-treatment.

1- Blood Pressure
Before ibogaine treatment, the patient’s blood pressure fluctuated over five days, with readings ranging from 109/76 mmHg to 128/88 mmHg. Post-ibogaine treatment showed a noticeable improvement in blood pressure stability, with readings consistently in the normal range (e.g., 128/86 mmHg). This suggests a positive impact on cardiovascular health.

2- Heart Rate
The patient’s heart rate was recorded daily throughout treatment, ranging from 69 to 95 beats per minute before treatment. Post-ibogaine treatment, the heart rate declined to a more stable range, with readings around 70 to 81 beats per minute. This signifies improved heart rate regulation, crucial for overall cardiovascular well-being.

3- Glucose Level
Blood glucose levels are essential indicators of metabolic health. Before ibogaine treatment, the patient’s glucose levels varied considerably, with readings as high as 136 mg/dL. Post-treatment, glucose levels improved significantly, with normal readings (e.g., 91 mg/dL). This suggests that ibogaine treatment may have positively influenced glucose control and metabolic stability.

4- Oxygen Saturation (SATO2)
SATO2 levels remained relatively stable throughout the treatment, indicating consistent oxygen saturation in the patient’s blood. There was no significant deviation from the normal range both before and after treatment, suggesting that ibogaine did not impact respiratory function adversely.

Cell blood counting, biochemistry parameters, liver function tests, and other parameters are missing in the report.

5- Urine Test for Drugs
The urine test results indicate that before ibogaine treatment, the patient tested positive for amphetamines (AMP) and benzodiazepines (BZD) but negative for opioids (OPI), methamphetamine (MET), cocaine (COC), and THC. After ibogaine treatment, the patient remained positive for AMP and BZD, while THC turned negative. This suggests ongoing use of amphetamines and benzodiazepines despite treatment.

Conclusion
In conclusion, the provided blood report indicates notable improvements in blood pressure, heart rate, and glucose levels following ibogaine treatment. However, the absence of data regarding various critical parameters limits a comprehensive assessment of the patient’s overall health. It is essential to address the continued positive tests for amphetamines and benzodiazepines and to provide appropriate support and monitoring for substance use issues. This report underscores the importance of a thorough clinical evaluation by healthcare professionals to assess the patient’s complete health status and treatment outcomes.

Accessibility Toolbar